CytoSorbents Corporation (CTSO)

[techxen]

Cytokine storm syndrome - narrative review

Published a few days ago in the Journal of Internal Medicine (a peer-reviewed scientific journal), this article is from physicians at Zhongda Hospital in Nanjing and Tongji Hospital in Wuhan, China. Tongji as you recall was one of the first hospitals to receive filters through the CMS arrangement.

Cytokine storm syndrome in coronavirus disease 2019: A narrative review
https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13144

"There is growing evidence that cytokine storms caused by the excessive production of inflammatory factors may participate in the pathogenesis of patients with COVID-19, which may be one of the key factors leading to the rapid worsening of the disease. Therefore, early identification and treatment of CSS may be crucial for improving the outcome of critically ill patients with COVID-19. Here, we summarize the pathogenesis, clinical manifestations of CSS, and highlight the current perspective about the recognition and potential therapeutics for CSS in COVID-19."

"CytoSorb®, a recently developed, commercially available haemoadsorption device that utilizes extracorporeal blood purification, is designed to reduce systemic cytokine burden. Numerous case reports and case series have suggested improved clinical outcomes with CytoSorb in patients with septic shock. Recently, CytoSorb® was also reported to be effective in a patient developed CSS after CAR T-cell application. Given that there is excessive production of various cytokines in patients with COVID-19, CytoSorb® may become a potential therapeutic candidate in COVID-19 patients complicated with CSS. Based on the previous experience in the treatment of patients with SARS and MERS and collected clinical experience in treatment of critical ill patients in China, the newly updated version of guidelines for the prevention, diagnosis, and treatment of pneumonia caused by COVID-19 in China also recommended that COVID-19 patients with high inflammatory response could consider to use extracorporeal blood purification technology for removal of cytokines and mitigate CSS."